Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Steroids ; 99(Pt B): 172-7, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25759118

ABSTRACT

Oxysterols and cholestenoic acids are oxidised forms of cholesterol with a host of biological functions. The possible roles of oxysterols in various neurological diseases makes the analysis of these metabolites in the central nervous system of particular interest. Here, we report the identification and quantification of a panel of twelve sterols in mouse cerebrospinal fluid (CSF) using liquid chromatography-mass spectrometry exploiting enzyme assisted derivatisation for sterol analysis technology. We found low levels of oxysterols and cholestenoic acids in CSF in the range of 5pg/mL-2.6ng/mL. As found in man, these concentrations are one to two orders of magnitude lower than in plasma.


Subject(s)
Cholestenes/cerebrospinal fluid , Cholesterol/analogs & derivatives , Sterols/cerebrospinal fluid , Animals , Cholestenes/blood , Cholestenes/chemistry , Cholesterol/blood , Cholesterol/cerebrospinal fluid , Cholesterol/chemistry , Enzymes/metabolism , Female , Hydroxycholesterols/cerebrospinal fluid , Male , Mice , Sterols/blood , Sterols/chemistry , Tandem Mass Spectrometry
2.
Neurology ; 68(18): 1481-7, 2007 May 01.
Article in English | MEDLINE | ID: mdl-17470750

ABSTRACT

BACKGROUND: Infection with HIV can result in a debilitating CNS disorder known as HIV dementia (HIV-D). Since the advent of highly active antiretroviral therapy (HAART), the incidence of HIV-D has declined, but the prevalence continues to increase. In this new era of HIV-D, traditional biomarkers such as CSF viral load and monocyte chemotactic protein 1 levels are less likely to be associated with dementia in patients on HAART and biomarkers that can predict HIV-D have not yet been identified. OBJECTIVE: To identify biomarkers that are associated with and can predict HIV-D. METHODS: We grouped patients with HIV based on changes in cognitive status over a 1-year period and analyzed sphingolipid, sterol, triglyceride, antioxidant, and lipid peroxidation levels in CSF. RESULTS: We found that increased levels of the vitamin E and triglyceride C52 predicted the onset or worsening of dementia. Elevated levels of sphingomyelin were associated with inactive dementia. Elevated levels of ceramide and the accumulation of 4-hydroxynonenals were associated with active dementia. CONCLUSIONS: We interpret these findings to indicate that early in the pathogenesis of HIV dementia, there is an up-regulation of endogenous antioxidant defenses in brain. The failure of this attempted neuroprotective mechanism leads to the accumulation of sphingomyelin and moderate cognitive dysfunction. The breakdown of this enlarged pool of sphingomyelin to ceramide and the accumulation of highly reactive aldehydes are associated with declining cognitive function. Thus, elevations in endogenous protective mechanisms may identify patients who are at increased risk of the development of HIV dementia.


Subject(s)
AIDS Dementia Complex/cerebrospinal fluid , AIDS Dementia Complex/diagnosis , Cerebrospinal Fluid/chemistry , HIV Infections/complications , HIV-1 , AIDS Dementia Complex/physiopathology , Adult , Aldehydes/analysis , Aldehydes/cerebrospinal fluid , Antioxidants/analysis , Antioxidants/metabolism , Biomarkers/cerebrospinal fluid , Brain/immunology , Brain/physiopathology , Brain/virology , Ceramides/analysis , Ceramides/cerebrospinal fluid , Female , Humans , Lipid Peroxidation , Male , Middle Aged , Oxidative Stress , Predictive Value of Tests , Sphingolipids/analysis , Sphingolipids/cerebrospinal fluid , Sterols/analysis , Sterols/cerebrospinal fluid , Triglycerides/analysis , Triglycerides/cerebrospinal fluid , Up-Regulation , Vitamin E/analysis , Vitamin E/cerebrospinal fluid
3.
Dement Geriatr Cogn Disord ; 19(5-6): 256-65, 2005.
Article in English | MEDLINE | ID: mdl-15785028

ABSTRACT

During the last years, several clinical studies have been published trying to elucidate the effect of statin treatment on amyloid precursor protein (APP) processing and metabolism of brain cholesterol in Alzheimer's disease (AD) in humans. We present an open biochemical study where 19 patients with AD have been treated with simvastatin (20 mg/day) for 12 months. The aim was to further investigate the effect of simvastatin treatment on cerebrospinal fluid (CSF) biomarkers of APP processing, AD biomarkers as total tau and tau phosphorylated at threonine 181, brain cholesterol metabolism as well as on cognitive decline in patients with AD. Despite biochemical data suggesting that treatment with 20 mg/day of simvastatin for 12 months does affect the brain cholesterol metabolism, we did not find any change in CSF or plasma levels of beta-amyloid (Abeta)(1-42). However, by analysis of APP isoforms, we found that statin treatment may favor the nonamyloidogenic pathway of APP processing. The relevance and mechanism between statin treatment and AD has to be further elucidated by using statins of different lipophility in different dosages over a longer period of time.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Protein Precursor/metabolism , Anticholesteremic Agents/administration & dosage , Brain Chemistry/drug effects , Cholesterol/metabolism , Simvastatin/administration & dosage , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Cognition , Cognition Disorders/cerebrospinal fluid , Cognition Disorders/drug therapy , Female , Humans , Lipids/blood , Male , Phosphorylation , Sterols/blood , Sterols/cerebrospinal fluid , tau Proteins/cerebrospinal fluid
4.
J Lipid Res ; 44(4): 793-9, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12562838

ABSTRACT

The side chain oxidized oxysterol 24S-hydroxycholesterol (24-OH-chol) is formed almost exclusively in the brain, and there is a continuous passage of this oxysterol through the circulation to the liver. 27-Hydroxycholesterol (27-OH-chol) is produced in most organs and is also taken up by the liver. The 27-OH-chol-24-OH-chol ratio is about 0.1 in the brain and about 2 in the circulation. This ratio was found to be about 0.4 in cerebrospinal fluid (CSF) of asymptomatic patients, consistent with a major contribution from the circulation in the case of 27-OH-chol. In accordance with this, we demonstrated a significant flux of deuterium labeled 27-OH-chol from plasma to the CSF in a healthy volunteer. Patients with a defective blood-brain barrier were found to have markedly increased absolute levels (up to 10-fold) of both 27-OH-chol and 24-OH-chol in CSF, with a ratio between the two sterols reaching up to 2. There was a significant positive correlation between the levels of both oxysterols in CSF and the albuminCSF-albuminplasma ratio. The 27-OH-cholCSF-24-OH-cholCSF ratio was found to be about normal in patients with active multiple sclerosis and significantly increased in patients with meningitis, polyneuropathy, or hemorrhages. Results are discussed in relation to the possible use of 24-OH-cholCSF as a surrogate marker of central nervous system demyelination and/or neuronal death.


Subject(s)
Blood-Brain Barrier , Cerebrospinal Fluid/chemistry , Sterols/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Cerebrospinal Fluid/physiology , Deuterium , Hemorrhage/cerebrospinal fluid , Humans , Hydroxycholesterols/blood , Hydroxycholesterols/cerebrospinal fluid , Male , Meningitis/cerebrospinal fluid , Middle Aged , Oxidation-Reduction , Polyneuropathies/cerebrospinal fluid , Sterols/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...